Soleno Therapeutics (SLNO) Preferred Stock Liabilities (2013 - 2016)

Soleno Therapeutics (SLNO) has 4 years of Preferred Stock Liabilities data on file, last reported at $13.0 in Q4 2016.

• On a quarterly basis, Preferred Stock Liabilities rose 160.0% year-over-year to $13.0 in Q4 2016; TTM through Dec 2016 was $13.0, a 160.0% increase from a year earlier, with the FY2016 full-year figure at $13.0, up 160.0% from the prior year.
• Preferred Stock Liabilities for Q4 2016 stood at $13.0, up from $5.0 in the prior quarter.
• Over the last five years, Preferred Stock Liabilities for SLNO reached as high as $15.4 million in Q3 2014 and fell as low as $5.0 in Q4 2015.
• Historically, Preferred Stock Liabilities has averaged $4.2 million across 4 years, with a median of $750006.5 in 2013.
• On a YoY basis, Preferred Stock Liabilities climbed as much as 160.0% in 2016 and fell as far as 160.0% in 2016.
• Year by year, Preferred Stock Liabilities stood at $1.5 million in 2013, then surged by 929.67% to $15.4 million in 2014, then plunged by 100.0% to $5.0 in 2015, then soared by 160.0% to $13.0 in 2016.
• Per Business Quant data, the three most recent Preferred Stock Liabilities figures were $13.0 in Q4 2016, $5.0 in Q4 2015, and $15.4 million in Q3 2014.